FY2025 Earnings Forecast for RANI Issued By Zacks Small Cap

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) – Analysts at Zacks Small Cap dropped their FY2025 EPS estimates for Rani Therapeutics in a report issued on Monday, November 10th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.35) for the year, down from their prior estimate of ($0.34). The consensus estimate for Rani Therapeutics’ current full-year earnings is ($1.01) per share. Zacks Small Cap also issued estimates for Rani Therapeutics’ FY2026 earnings at ($0.18) EPS.

Several other equities analysts have also issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Rani Therapeutics in a research note on Tuesday, October 21st. Wall Street Zen raised shares of Rani Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rani Therapeutics in a research note on Friday, October 31st. Finally, Maxim Group increased their target price on shares of Rani Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, October 20th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Rani Therapeutics Trading Up 9.3%

RANI opened at $2.12 on Thursday. The firm has a market cap of $152.36 million, a price-to-earnings ratio of -2.68 and a beta of 0.38. Rani Therapeutics has a 12 month low of $0.39 and a 12 month high of $3.87. The stock has a fifty day moving average price of $1.09 and a 200-day moving average price of $0.77.

Rani Therapeutics (NASDAQ:RANI) last posted its earnings results on Thursday, November 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03).

Institutional Investors Weigh In On Rani Therapeutics

Large investors have recently bought and sold shares of the company. Kestra Private Wealth Services LLC increased its holdings in Rani Therapeutics by 16.3% in the 1st quarter. Kestra Private Wealth Services LLC now owns 139,156 shares of the company’s stock worth $175,000 after buying an additional 19,536 shares during the period. King Luther Capital Management Corp boosted its holdings in shares of Rani Therapeutics by 75.8% in the 1st quarter. King Luther Capital Management Corp now owns 58,000 shares of the company’s stock valued at $73,000 after acquiring an additional 25,000 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Rani Therapeutics by 102.9% in the second quarter. Janney Montgomery Scott LLC now owns 55,200 shares of the company’s stock worth $28,000 after acquiring an additional 28,000 shares during the period. Well Done LLC purchased a new position in shares of Rani Therapeutics during the second quarter worth $27,000. Finally, CWA Asset Management Group LLC lifted its position in Rani Therapeutics by 80.0% during the third quarter. CWA Asset Management Group LLC now owns 150,000 shares of the company’s stock valued at $75,000 after purchasing an additional 66,667 shares during the period. Hedge funds and other institutional investors own 30.19% of the company’s stock.

Insiders Place Their Bets

In other news, Director Mir A. Imran purchased 2,083,334 shares of the company’s stock in a transaction on Thursday, October 23rd. The shares were acquired at an average price of $0.60 per share, for a total transaction of $1,250,000.40. Following the purchase, the director owned 2,083,334 shares in the company, valued at $1,250,000.40. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder South Cone Investments Limited sold 4,000,000 shares of the stock in a transaction dated Tuesday, October 21st. The shares were sold at an average price of $2.77, for a total value of $11,080,000.00. Following the completion of the transaction, the insider directly owned 2,379,194 shares in the company, valued at $6,590,367.38. This represents a 62.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 45.08% of the stock is owned by insiders.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.